secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003236
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion amends notes/RIFAs with cash & revenue covenants, FDA/France deadlines; reports AUDACITY trial topline results
--------------------------------------------------------------------------------

- Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.
- Deadlines: French marketing authorization by Dec 31, 2025; FDA US marketing authorization by June 30, 2026.
- Amendment fee: 5% fully-diluted shares to investors after $12M+ offering by Feb 15, 2025; else Series A-1 preferred redeemable Dec 31, 2026.
- RTW gets second board seat; Jason Richey appointed to board alongside Nicholas Lewin.
- Announced topline results from AUDACITY trial of Allurion Balloon; details in press release Exhibit 99.4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525003236/0001193125-25-003236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525003236/d896057d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer